USE OF CMV HYPERIMMUNOGLOBULINS (CYTOTECT) AS PREEMPTIVE TREATMENT OF CMV INFECTION IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE CENTRE EXPERIENCE

被引：0
|
作者：
Desnica, Lana [1 ]
Durakovic, Nadira [1 ]
Peric, Zinaida [1 ]
Serventi-Seiwerth, Ranka [1 ]
Roncevic, Pavle [1 ]
Sertic, Dubravka [1 ]
Mikulic, Mirta [1 ]
Pulanic, Drazen [1 ]
Vrhovac, Radovan [1 ]
机构：
[1] Univ Hosp Ctr Zagreb, Zagreb, Croatia
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P405
引用
收藏
页码：430 / 431
页数：2
相关论文
共 50 条
  • [31] CMV resistance in patients after allogeneic haematopoietic stem cell transplantation
    Hubacek, P.
    Kouba, M.
    Boutolleau, D.
    Pliskova, L.
    Vejrazkova, E.
    Keslova, P.
    Sedlacek, P.
    Cetkovsky, P.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 : S78 - S78
  • [32] Incidence of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell recipients at low risk of CMV infection
    T Mori
    S Okamoto
    R Watanabe
    R Yamazaki
    Y Tsukada
    H Nagayama
    A Ishida
    Y Ikeda
    [J]. Bone Marrow Transplantation, 2002, 29 : 1005 - 1006
  • [33] Cytomegalovirus (CMV) impact on clinical outcomes and resource use after allogeneic hematopoietic cell transplantation: The influence of recurrent episodes of CMV infection
    de Miguel, Carlos
    Royuela, Ana
    Francisca Portero, Maria
    Luis Cruz, Juan
    Esther Martinez-Munoz, Maria
    Sanchez Romero, Maria Isabel
    Bautista, Guiomar
    Cabrera, Rafael
    Duarte, Rafael F.
    [J]. BONE MARROW TRANSPLANTATION, 2018, 53 : 550 - 551
  • [34] CMV resistance in patients after allogeneic haematopoietic stem cell transplantation
    Hubacek, P.
    Kouba, M.
    Boutolleau, D.
    Pliskova, L.
    Vejrazkova, E.
    Keslova, P.
    Sedlacek, P.
    Cetkovsky, P.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2015, 70 : S125 - S126
  • [35] CMV infections after hematopoietic stem cell transplantation
    P Ljungman
    [J]. Bone Marrow Transplantation, 2008, 42 : S70 - S72
  • [36] THE CLINICAL AND FINANCIAL BURDEN OF PREEMPTIVE MANAGEMENT OF CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
    Barrett, A.
    Jain, N.
    Ito, S.
    Lu, K.
    Muranski, P.
    Childs, R.
    Hourigan, C.
    Haggerty, J.
    Ramos, C.
    Cook, L.
    Battiwalla, M.
    [J]. BONE MARROW TRANSPLANTATION, 2014, 49 : S331 - S331
  • [37] CMV infections after hematopoietic stem cell transplantation
    Ljungman, P.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 1) : S70 - S72
  • [38] How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation
    Einsele, Hermann
    Ljungman, Per
    Boeckh, Michael
    [J]. BLOOD, 2020, 135 (19) : 1619 - 1629
  • [39] Human cytomegalovirus DNAemia and preemptive treatment of CMV infection in children after hematopoietic stem-cell transplantation: Is any question settled?
    Cesaro, Simone
    Abate, Davide
    Mengoli, Carlo
    [J]. BLOOD, 2008, 111 (08) : 4419 - 4419
  • [40] Clinical Impact and Burden of CMV Infection on the Use of Resources in Allogeneic Hematopoietic Cell Transplantation
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 19 - 20
12345